Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices
Drug Research
Return to: PBR Home | Drug Research
Today in Drug Research

Drug Research

New European consortium to help advance development of GSK/NIH Ebola vaccine candidate GlaxoSmithKline (GSK) and three leading research institutions have formed a new European consortium to help advance development of an Ebola vaccine candidate, which is being jointly-developed by GSK and the US National Institutes of Health (NIH). Drug Research > Drug Delivery > News

Latest Drug Research News by Sector

Select a sector from the list or browse by sector below:

Drug Delivery

Amgen seeks approval for myeloma drug Kyprolis in US and Europe
By PBR Staff Writer
Amgen and its subsidiary Onyx Pharmaceuticals have submitted a supplemental new drug application (sNDA) to the US Food and Drug Administration (FDA) as well as a marketing authorization application (MAA) to the European Medicines Agency (EMA) seeking approval for Kyprolis (carfilzomib) for Injection.
News
FDA accepts for priority review Sanofi and Regeneron's BLA for hypercholesterolemia drug Praluent
By PBR Staff Writer
The US Food and Drug Administration (FDA) has accepted for priority review the biologics license application (BLA) for Sanofi and Regeneron's Praluent (alirocumab), which is designed to treat patients with hypercholesterolemia.
News

Drug Discovery & Development

CEL-SCI secures approval in Romania to start Phase III Multikine trial
By PBR Staff Writer
US-based CEL-SCI has received clearance from the Romanian Ministry of Health to start patient enrollment in its Phase III trial of its investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Injection) to treat advanced primary head and neck cancer.
News
Opsona starts OPN-305 Phase I/II trial to treat myelodysplastic syndrome
By PBR Staff Writer
Opsona Therapeutics has commenced a Phase I/II clinical trial of its lead drug candidate, OPN-305, in second-line lower (Low and intermediate-1) risk myelodysplastic syndrome (MDS) patients.
News